関連する実験動画
Updated: May 29, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
プロトロンビン複合体の濃縮物によるリバロキサバンとダビガトランの逆転:健康な被験者でのランダム化,プラセボ対照,クロスオーバー研究
Elise S Eerenberg1, Pieter W Kamphuisen, Meertien K Sijpkens
1Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands. e.s.eerenberg@amc.uva.nl
Circulation
|September 9, 2011
まとめ
プロトロンビン複合濃縮 (PCC) は,リバロキサバンを効果的に逆転させます.
科学分野:
- 薬理学 薬理学とは
- 血液学 ヘマトロジ
- クリニカル・メディシン 臨床医学
背景:
- リバロキサバンとダビガトランは,血栓塞栓症の予防と治療に使用される新しい経口抗凝固剤です.
- 重要な制限は,出血の緊急事態に対する容易に入手可能な解毒剤の欠如です.
- プロトロンビン複合物濃縮 (PCC) は,潜在的な逆転剤として調査されています.
研究 の 目的:
- リバロキサバンとダビガトランの抗凝固剤効果を逆転させるPCCの有効性を評価する.
- 健康なボランティアの特定の凝固パラメータに対するPCCの影響を評価する.
主な方法:
- 12人の健康な男性ボランティアを対象としたランダム化,ダブルブラインド,プラセボ対照試験です.
- 参加者はリバロキサバンまたはダビガトランを投与され,その後PCCまたは塩水投与を受けた.
- 薬剤およびPCC/塩水投与前および後に凝固検査を実施した.
主要な成果:
- PCCは,リバロキサバンによるプロトロンビン時間の延長を完全かつ即座に逆転させ,内生性トロビンポテンシャルを正常化させた.
- 塩水は,リバロキサバンの抗凝固作用に影響を与えなかった.
- PCCは,aPTT,ECT,TTを含むダビガトランの影響を受けた凝固検査を復元しませんでした.
結論:
- PCCは,健康な被験者において,リバロキサバンの抗凝固効果を迅速かつ効果的に逆転させます.
- PCCは,試験用量でのダビガトランの抗凝固作用の逆転に有意な効果を示さなかった.
- ダビガトランの有効な逆転剤を特定するために,さらなる研究が必要になる可能性があります.
関連する概念動画
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:16Crossover Experiments
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...